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The effect of dialysis dose and membrane flux on nutritional pa-
rameters in hemodialysis patients: Results of the HEMO Study.
Background. The effect of standard or high dialysis dose and
low or high dialysis flux on nutritional status was ascertained in
1846 maintenance hemodialysis patients enrolled in the HEMO
Study.
Methods. Serum albumin levels, equilibrated protein
catabolic rate, and postdialysis weight were obtained monthly,
while adjusted protein and energy intake, self-reported appetite
assessment, upper arm circumference, and calf circumference
were obtained yearly. To account for patient attrition due to
death or transfer, three statistical models were used to test the
effects of the study interventions on longitudinal changes in
nutritional parameters.
Results. During the first 3 years of follow-up, neither mean
serum albumin levels, which declined by 0.21 g/dL, nor mean
postdialysis weight, which declined by 2.7 kg, were significantly
affected by either study intervention. Mean levels of all an-
thropometric measures declined during follow-up. For years 1,
2, and 3, the mean ± SE declines in upper arm and calf cir-
cumferences were 0.35 ± 0.16 cm (P = 0.031) and 0.31 ± 0.13
(P = 0.015) cm less, respectively, in the high flux compared to the
low flux group. Appetite scores and mean equilibrated protein
catabolic rate also declined in all randomized groups; however,
the average decline in equilibrated protein catabolic rate dur-
ing years 1, 2, and 3 was 0.019 ± 0.007 g/kg/day less in the high
dose than the standard dose group (P = 0.007). There was no
significant change in either mean energy or protein intake from
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diet records over time, and neither parameter was affected by
the study interventions.
Conclusion. Although the dose and flux interventions may
subtly influence certain nutritional parameters, neither inter-
vention prevented deterioration in nutritional status over time.
Between one third and three fourths of maintenance
hemodialysis patients show some signs, symptoms, or lab-
oratory evidence of malnutrition [1–5]. Despite ongoing
efforts to improve the quality of care of hemodialysis pa-
tients, mean serum albumin levels have not improved sig-
nificantly in these patients over the past 9 years [1]. Many
investigators believe that serum albumin is a marker
for pathologic processes such as inflammation, subopti-
mal nutritional intake, and metabolic acidosis. Several
studies have demonstrated a relationship between hy-
poalbuminemia and both poor nutritional intake and
inflammation [6–8]. There is ample evidence linking hy-
poalbuminemia with both atherosclerotic disease [9–11]
and congestive heart failure [9] and linking hypoalbu-
minemia with infectious complications [4, 12, 13].
Although the benefits of erythropoietin alpha on nu-
tritional status in hemodialysis patients have been well
documented, the effects of oral and parenteral sup-
plementation and the correction of acidosis are uncer-
tain [2, 14–23]. An increased dose of dialysis and the
use of biocompatible membranes have also been used
to enhance nutritional status in hemodialysis patients.
However, several randomized and nonrandomized clin-
ical trials have shown conflicting results regarding the
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impact of the study intervention on nutritional parame-
ters [24–26].
Analysis of the primary and secondary results of the
Hemodialysis (HEMO) Study, a prospective randomized
clinical trial, did not show a beneficial effect of either
dialysis dose or dialysis flux on mortality or morbidity
or the composite endpoint of the first 15% decline in
serum albumin or all-cause mortality. In this manuscript,
a detailed analysis of effects of the HEMO Study inter-
ventions on nutritional parameters is presented. In ad-
dition, the effects of the interventions on the changes in
serum albumin level, body weight postdialysis, appetite
assessment, protein and energy intake and anthropomet-
ric measurements in the entire HEMO Study cohort are
analyzed.
METHODS
Design
The design and methods of the HEMO Study have
been published [27, 28]. In brief, the HEMO Study was a
multicenter, prospective, randomized, 2 × 2 factorial clin-
ical trial that evaluated the efficacy of the delivered dose
of dialysis (“standard group,” equilibrated Kt/V (eKt/V)
urea of 1.05 or single-pool Kt/V (spKt/V) of about 1.25,
depending on ultrafiltration versus “high group,” eKt/V
urea of 1.45 or spKt/V of about 1.65) and dialysis mem-
brane flux (“low group,” b 2-microglobulin (b 2-m) clear-
ance of less than 10 mL/min versus “high group,” b 2-m
clearance of greater than 20 mL/min) in reducing the mor-
bidity and mortality of hemodialysis patients. Patients
were randomly allocated in equal proportions into the
two dose and flux groups.
Baseline
Eligibility requirements were an age between 18 and
80 years, receiving thrice weekly in-center hemodialysis,
and on maintenance hemodialysis for at least 3 months
at study entry. Patients were excluded during baseline if
residual urea clearance exceeded 1.5 mL/min per 35 L of
urea volume, serum albumin <2.6 g/dL by nephelometry,
if they failed to achieve an eKt/V > 1.30 within 41/2 hours
for two of three consecutive monitored dialyses targeting
the high dose dialysis goal, or if serious comorbid medical
conditions were present. These latter conditions included
active malignancies requiring chemotherapy or radiation
therapy, treated class IV congestive heart failure, unsta-
ble angina pectoris, symptomatic acquired immunodefi-
ciency syndrome (AIDS), active systemic infections such
as tuberculosis or systemic fungal infection, chronic pul-
monary disease requiring supplemental oxygen, cirrho-
sis with encephalopathy, or abnormal prothrombin time;
and scheduled living donor transplant within the period
of the study. All 15 participating clinical centers received
local Institutional Review Board approval prior to ini-
tiating the study and each participant provided written
informed consent.
Interventions
Target eKt/V was achieved by manipulating both dia-
lyzer clearance and treatment time. The targeted dialysis
dose was achieved in as short a time as possible, with
a minimum treatment time of 21/2 hours. Adherence to
dose intervention was monitored by monthly urea kinetic
modeling. b 2-m clearance was measured every 2 months
for high flux dialyzers and every 6 months for low flux
dialyzers. Reuse of dialyzers was permitted, but the num-
ber of reuses was limited in the high flux arm to meet the
high flux b 2-m clearance targets [27].
Outcomes
The primary outcome for the HEMO Study was all-
cause mortality. The main secondary outcome related to
nutritional status was the first significant decline in serum
albumin level (defined as > 15% reduction from baseline)
or all-cause mortality. Thresholds for declines in seven ad-
ditional nutritional outcomes, defined in Tables 1 and 2,
were chosen to be clinically significant and to provide suf-
ficient clinical events for adequate statistical power prior
to the analyses relating these outcomes to the treatment
group.
Nutritional measurements
The nutritional portions of the study were coordinated
by the Nutrition Coordinating Center [29]. Each clinical
center had one or more dietitians who received standard-
ized training in the collection and review of 2-day diet
diary assisted recalls, utilization of the nutrient analysis
software, and the anthropometric procedures. Dietitians
were certified at study initiation and recertified annually
in each of these areas. Standardized coding and a query
system were used to assure consistency over time and
across sites in the collection of nutritional data. Details
of the nutritional measurements have been described [29]
and are summarized briefly below.
Diet records
Two-day diet diary-assisted recalls were obtained dur-
ing the baseline period while patients were receiving their
original dialysis prescription and then yearly thereafter.
Patients recorded their food and beverage intake, includ-
ing nutritional supplements, during a 2-day period that in-
cluded one dialysis day and one nondialysis day. The diet
diary was reviewed by the study dietitian and entered
at each clinical center into customized versions of Nutri-
tionist IV (version 4.0a, from March 1995 to July 1999)
or Nutritionist V software (versions 2.0h to 2.1.1h from
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Table 1. Time-to-event analysis (models 2 and 3): Effect of dose
Data including deaths Data censoring death
(model 2) (model 3)
Threshold
Factor for decline Nutritional events % Deaths % RR 95% CI P value RR 95% CI P value
aNephelometry albumin g/dL 15% 26.8 28.0 1.03 0.91–1.16 0.66 1.05 0.88–1.26 0.59
aPostdialysis weight kg 10% 31.2 25.8 1.02 0.91–1.16 0.71 1.09 0.92–1.29 0.31
aEquilibrated protein catabolic 15% 84.6 6.9 0.86 0.78–0.95 0.0023 0.89 0.80–0.98 0.021
rate g/kg/day
bAdjusted energy intake 15% 37.6 29.9 0.96 0.85–1.08 0.52 1.05 0.90–1.20 0.52
kcal/kg/day
bAdjusted protein intake 15% 40.4 28.2 0.93 0.82–1.04 0.20 0.95 0.80–1.09 0.47
g/kg/day
bCalf circumference cm 4% 29.4 30.4 0.88 0.76–1.00 0.042 0.85 0.68–1.02 0.090
bUpper arm circumference cm 5% 33.8 27.7 0.89 0.78–1.01 0.073 0.87 0.71–1.03 0.11
bAppetite assessment 1 point 28.0 32.0 1.01 0.89–1.13 0.85 1.02 0.90–1.14 0.76
(5-point Likert scale)
Each analysis was stratified by center and included the following covariates: age, gender, black vs. nonblack race, diabetic status, ICED score, baseline nephelometry
albumin, and the variable baseline nephelometry albumin multiplied by follow-up time.
Data including deaths: Effect of dose on the composite event of either death or a decline in the nutritional factor past a designated percentage.
Data censoring deaths: Effect of dose on a decline in the nutritional factor past a designated percentage when deaths are censored.
aDenote variables analyzed using regular Cox regression models.
bDenote variables analyzed using interval censoring models.
Table 2. Time-to-event analysis (models 2 and 3): Effect of flux
Data including deaths Data censoring death
(model 2) (model 3)
Threshold
Factor for decline Nutritional events % Deaths % RR 95% CI P value RR 95% CI P value
aNephelometry albumin g/dL 15% 26.8 28.0 0.92 0.82–1.05 0.21 0.93 0.77–1.11 0.41
aPostdialysis weight kg 10% 31.2 25.8 0.92 0.82–1.04 0.20 1.04 0.88–1.23 0.62
aEquibrated protein catabolic rate g/kg/day 15% 84.6 6.9 1.09 0.99–1.20 0.10 1.11 1.00–1.22 0.055
bAdjusted energy intake kcal/kg/day 15% 37.6 29.9 0.95 0.84–1.06 0.40 0.96 0.81–1.11 0.59
bAdjusted protein intake g/kg/day 15% 40.4 28.2 0.89 0.78–1.01 0.055 0.87 0.73–1.02 0.090
bCalf circumference cm 4% 29.4 30.4 0.81 0.69–0.93 0.0016 0.85 0.68–1.02 0.087
bUpper arm circumference cm 5% 33.8 27.7 0.80 0.68–0.92 0.0008 0.79 0.63–0.95 0.0093
bAppetite assessment (5-point Likert scale) 1 point 28.0 32.0 1.10 0.92–1.27 0.27 1.10 0.93–1.27 0.26
Each analysis was stratified by center and included the following covariates: age, gender, black vs. nonblack race, diabetic status, ICED score, baseline nephelometry
albumin, and the variable baseline nephelometry albumin multiplied by follow-up time.
Data including deaths: Effect of flux on the composite event of either death or a decline in the nutritional factor past a designated percentage.
Data censoring deaths: Effect of flux on a decline in the nutritional factor past a designated percentage when deaths are censored.
aDenote variables analyzed using regular Cox regression models.
bDenote variables analyzed using interval censoring models.
August 1999 to end of study; all versions from First Data
Bank, San Bruno, CA, USA). Nutrient analysis results,
including protein and energy intake, were transmitted to
the Data Coordinating Center for further quality assur-
ance and analyses.
Kinetic modeling and protein catabolic rate data. At
baseline and then monthly after randomization, spKt/V
and double-pool Kt/V (dpKt/V) was measured using for-
mal urea kinetic modeling [30]. Protein intake was also
estimated monthly from the normalized protein catabolic
rate calculated from the patient’s urea generation rate by
urea kinetic modeling [30, 31]. Both single-pool protein
catabolic rate and equilibrated protein catabolic rate urea
kinetics were used to estimate protein catabolic rate [30].
Anthropometric measurements. Pre- and postdialysis
weights were recorded monthly. Other anthropometric
measurements were obtained annually using standard
techniques after dialysis at baseline and then yearly after
randomization [32]. These measures included stature (if
the patient was an amputee, height was estimated from
knee height and the formula of Chumlea, Guo, and Stein-
baugh [33]) triceps, biceps and subscapular skinfolds,
midarm circumference, elbow breadth, and calf circum-
ference using standard techniques [34]. Standardized
body weight was calculated using actual body weight
when the patient weighed between 90% and 120% of
standard body weight, defined as the median from the
National Health and Nutrition Examination Survey II
data [35]. When the patient was outside this range of stan-
dard body weight, adjusted body weight was calculated
to standardize nutrient intake data using the formula:
ABW = [(Actual weight − SBW) × 0.25] + SBW
where ABW is adjusted body weight and SBW is stan-
dardized body weight. Utilization of this formula in-
creased the likelihood that an underweight patient would
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be prescribed an adequate diet and that an overweight pa-
tient would not receive excessive amounts of nutrients.
Anthropometric volume was obtained from the postdial-
ysis weight, height, age, and gender using the Watson
formula [36].
Other data. Pre- and post-dialysis blood pressure,
treatment time, membrane type and dry weight were
obtained from dialysis records. Diabetic status, duration
of dialysis, medical comorbidity score using the ICED
(Index of Co-Existing Disease), subjective assessment of
appetite using the Appetite and Diet Assessment Tool
(ADAT), and use of antihypertensive medications were
obtained by patient interview and chart review. ICED
is a comorbidity classification system that evaluates the
severity of 19 individual disease categories attained from
a review of medical records using an ordinal scale [28].
The ADAT is a 44-item questionnaire regarding appetite
and eating habits [37]. Subjective assessment of appetite
was rated on a 5-point Likert scale: “very good,” “good,”
“fair,” “poor,” and “very poor.”
Two nutritional action items were defined for the study.
An action item was reached if the serum albumin level
declined by at least 10% from baseline on two consecu-
tive monthly measurements or if postdialysis body weight
decreased by ≥5% or ≥2.5 kg from baseline on two con-
secutive monthly measurements. If the patient reached an
action item, the dietitian first assessed problems with the
patient’s nutritional intake, then provided additional oral
nutritional supplements if deemed appropriate and fi-
nally considered the need for parenteral nutrition. While
these interventions were not rigorously prespecified, the
interventions suggested were based on the dietitian’s clin-
ical judgment of how to treat the patient for the action
item.
Statistical analysis
General. Baseline levels for serum albumin, weight,
and equibrated protein catabolic rate were averaged over
the first two baseline kinetic modeling sessions while
patients remained on their original prestudy dialysis
prescriptions [28]. All P values are two-sided without
adjustment for multiple comparisons. Because eight out-
comes are considered for the comparisons of the dose
and flux groups, differences between treatment groups
are emphasized only when P < 0.01.
Longitudinal analyses. Assessment of longitudinal
changes in dialysis patients is complicated by their high
rate of attrition due to death, as well as transplantation
and transfer to nonparticipating dialysis facilities. Pa-
tients providing data at different follow-up times are not
strictly comparable, as survivors to later follow-up will
have been, on average, in better health at prior assess-
ments. Accordingly, three alternative methods with dif-
ferent approaches to accounting for attrition were used
to evaluate changes in nutritional status.
For each factor and each of the three methods, we first
tested the interaction between the dose and flux inter-
ventions. For factors with no significant interaction (at
P < 0.05), we present the overall treatment group com-
parisons (i.e., we compare the dose groups combining
patients in both flux groups), and we compare the flux
groups combining patients in both dose groups. Effects of
randomized groups were tested with adjustment for seven
prespecified baseline factors: age, gender, race, years on
dialysis, diabetes, ICED score, excluding diabetes, and
albumin, as well as the baseline value of the nutritional
variable being analyzed. Time-to-event analyses (meth-
ods 2 and 3 below) were also stratified by clinical center
and adjusted for the interaction of baseline albumin with
follow-up time.
Method 1 was an analysis of mean change. Mean
changes from baseline to follow-up were estimated for
each nutritional parameter using a statistical model that
accounted for “informative censoring” due to attrition
[38–40]. To reduce complications from multiple hypothe-
sis testing, the effects of the dose and flux interventions on
the mean changes in annually measured variables were
averaged over the year 1, 2, and 3 assessments. Changes
from baseline in the monthly variables (weight, albumin,
and equilibrated protein catabolic rate) were first aver-
aged to obtain quarterly means over successive 3-month
intervals, and the effects of the interventions averaged
over the 12 quarters through year 3. We performed sensi-
tivity analyses to examine the robustness of the results of
method 1 to alternative assumptions for changes in nutri-
tional parameters following dropout [40–42]. Details are
provided in the appendix.
Method 2 was a time-to-event analysis of composite
events, including designated declines in nutritional in-
dices or death. In methods 2 and 3, the time until the
nutritional parameter declines to a prespecified thresh-
old (see Tables 1 or 2) or beyond is determined. Method 2
evaluates the time from randomization until the compos-
ite end point occurs. This end point is defined as either
death or reaching the designated nutritional threshold.
Incorporating death in the composite outcome eliminates
bias caused by censoring deaths, but some deaths may be
unrelated to nutritional status, complicating the interpre-
tation of the analysis.
Method 3 was a time-to-event analysis of designated
nutritional declines while censoring death. This method
is similar to method 2, but deaths are censored as a com-
peting risk [43]. This avoids the interpretational problem
of method 2, where deaths from nonnutritional causes
are mixed with nutritional events. However, because the
outcome (time to the designated nutritional decline) may
be correlated with censoring due to death, this analysis
may be biased due to informative censoring [44].
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Table 3. Baseline characteristics of nutrition variables
Number of missing
Factors data pointsa All Males Females P value
Nephelometry albumin g/dL — 3.62 ± 0.36 3.70 ± 0.37 3.56 ± 0.34 <0.0001
Postdialysis weight kg — 69.2 ± 14.7 72.1 ± 13.6 66.8 ± 15.1 <0.0001
Normal protein catabolic rate g/day — 55.1 ± 16.3 61.5 ± 16.5 50.2 ± 14.4 <0.0001
Equilibrated protein catabolic rate g/kg/day — 1.03 ± 0.24 1.04 ± 0.24 1.03 ± 0.24 0.43
Unadjusted energy intake kcal/day 2 1528 ± 548 1726 ± 577 1374 ± 470 <0.0001
Adjusted energy intake kcal/kg/day 2 22.7 ± 8.2 23.7 ± 8.3 21.9 ± 8.0 <0.0001
Unadjusted protein intake g/day 2 62.8 ± 23.3 70.5 ± 24.8 56.9 ± 20.2 <0.0001
Adjusted protein intake g/kg/day 2 0.93 ± 0.35 0.97 ± 0.35 0.90 ± 0.34 <0.0001
Calf circumference cm 34 33.3 ± 4.0 33.7 ± 3.6 33.1 ± 4.3 <0.0001
Upper arm circumference cm 5 30.1 ± 5.1 29.6 ± 4.2 30.5 ± 5.6 <0.0001
Biceps skinfolds mm 74 10.0 ± 6.7 7.3 ± 5.1 12.1 ± 7.1 <0.0001
Triceps skinfolds mm 93 16.4 ± 7.9 12.6 ± 6.4 19.5 ± 7.7 <0.0001
Subscapular skinfolds mm 223 17.3 ± 8.3 15.6 ± 7.5 18.6 ± 8.7 <0.0001
Appetite assessment (5-point Likert Scale) —
“Very poor” 33 (1.8%) 13 (1.6%) 20 (1.9%) 0.0007
“Poor” 130 (7.4%) 50 (6.2%) 80 (7.7%)
“Fair” 440 (23.8%) 166 (20.5%) 274 (26.4%)
“Good” 702 (38.0%) 304 (37.6%) 398 (38.3%)
“Very Good” 541 (29.3%) 275 (34.0%) 266 (25.6%)
a1846 patients enrolled at baseline.
P value for male versus female comparison of each variable.
For both methods 2 and 3, monthly parameters were
analyzed by Cox regression [45] censored at transplan-
tation or transfer out of the HEMO Study dialysis unit
(plus death for method 3). For annually measured pa-
rameters, a double-censoring model was used in which
the nutritional events were stipulated as occurring at an
unknown time during the year prior to the occurrence of
the designated decline in the nutritional parameter [46].
Methods 1, 2, and 3 provide complementary interpreta-
tions, and we limit definitive inferences to the results that
were common to all three methods. An important dis-
tinction is that method 1 is sensitive both to declines and
improvements in nutritional parameters, while methods
2 and 3 are sensitive only to declines in nutritional status.
RESULTS
Patient characteristics
A total of 1846 were randomized into the study over
a 67-month period (March 1995 to October 2000). A de-
tailed assessment of the demographic characteristics of
the study cohort has been reported [27]. In brief, the
randomized patients had a mean (±SD) age of 57.6 ±
14.0 years, with 56% women, 63% African American,
and 45% with either type I or type II diabetes. The mean
duration of dialysis at baseline was 3.7 ± 4.4 years. There
was good separation between the standard and high dose
arms of the study, with mean eKt/V values of 1.16 ± 0.08
and 1.53 ± 0.09, respectively, and mean spKt/V values of
1.32 ± 0.09 and 1.71 ± 0.11, respectively. There was also
good separation between the low and high flux arms of
the study, with mean b 2-m clearances of 3.4 ± 7.2 mL/min
and 33.8 ± 11.4 mL/min, respectively [27]. There was no
statistically significant effect of either the dose or the flux
intervention on overall mortality [27].
Baseline nutritional findings
Baseline nutritional characteristics of men and women
study participants are shown in Table 3. The mean
(±SD) serum albumin levels in women and men were
3.56 ± 0.34 g/L and 3.70 ± 0.37 g/L, respectively, by neph-
elometry; 3.91 ± 0.31 g/L and 4.03 ± 0.34 g/L, respectively,
using the bromcresol green (BCG) method (P = <0.0001
for each). Men had a higher mean postdialysis weight,
equilibrated protein catabolic rate, unadjusted and ad-
justed protein and energy intake, calf circumference and
a higher percentage of “very good” appetite compared
to women while women had a greater mean upper arm
circumference compared to men (Table 3). None of the
baseline nutritional characteristics listed in Table 3 dif-
fered significantly between the dose or flux interventions
among the entire cohort or by gender.
Five of the eight nutritional outcome parameters were
collected on a yearly basis. Some patients were random-
ized too late in the study to reach their year 2 (13.9%)
or year 3 (24.0%) visits. Among the remaining patients,
12.6%, 26.2%, and 35.4% died prior to their years 1-, 2-,
and 3-year visits, respectively. In addition, 7.4%, 13.0%,
and 14.9% additional patients left the study due to kidney
transplantation or transfer to a nonparticipating dialysis
center. Among those patients remaining in the study, the
percentage of patients missing the annually measured nu-
tritional status indices ranged from 5.0% to 7.0% at year
1, 4.7% to 5.7% at year 2, and 4.6% to 6.3% at year
3. Altogether, the proportion of annually measured pa-
rameters lost due to attrition or absent measurements
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Fig. 1. The change in serum albumin levels
by the nephelometry method is shown for the
dose intervention (A) and the flux interven-
tion (B). In each panel, the adjusted values
for the low or standard group are denoted (•)
and the adjusted values for the high group are
denoted (◦). Diamonds indicate unadjusted
mean changes for those patients surviving to
their respective follow-up time points in the
low or standard group () and high group (
).
ranged from 25.1% to 27.2% at year 1, 43.3% to 45.0%
at year 2, and 54.8% to 56.6% at year 3. The percent-
ages of patients missing the monthly measurements of
albumin, weight, and equilibrated protein catabolic rate
were slightly lower.
Nutritional action items occurred in 840 patients for
serum albumin and in 893 patients for body weight. There
were no statistically significant differences in the number
of action items between either the dose or flux groups.
Longitudinal changes
Analysis of mean change under the informative censor-
ing model (model 1). The estimated mean changes for
seven of the eight nutritional outcomes based on the in-
formative censoring model (see Appendix), and adjusted
for baseline demographic and comorbidity covariates, are
presented in Figures 1 to 7. For purposes of compari-
son, the raw mean changes, calculated without any ad-
justment for attrition or covariates, are also provided.
Table 4 presents the average attrition-adjusted dif-
ferences between treatment groups among the mean
changes for all eight nutritional outcomes over years 1, 2,
and 3.
As shown in Figure 1, the mean serum albumin level
declined by approximately 0.21 g/dL among all patients
between baseline and 3 years. The average of the treat-
ment effects for either the dose and flux intervention on
serum albumin over the first 3 years were not statistically
significant (Table 4). The unadjusted mean decline in the
serum albumin at 3 years was substantially smaller, at ap-
proximately 0.10 g/dL. The larger mean decline under the
informative censoring model reflects its inclusion of all
randomized patients, while the unadjusted mean change
is restricted to patients who survived to 3 years and who
likely had better nutritional status during follow-up than
those patients who died prior to 3 years.
The mean postdialysis weight declined by about 2.7 kg
at 3 years under the informative censoring model (Fig. 2),
with no significant differences between the randomized
treatment groups through year 3.
The mean equilibrated protein catabolic rate for the
entire cohort declined by approximately 0.1 g/kg/day dur-
ing the first 3 years of follow-up (Fig. 3). At 2 months,
the mean decline was 0.025 ± 0.008 (P = 0.0019) greater
in the standard dose group compared to the high dose
group, and this difference between dose groups generally
persisted for the remainder of the 3 years of follow-up.
Mean levels of adjusted protein and energy intake did
not significantly change over the first 3 years of the study
and did not differ significantly between the dose and flux
groups (Figs. 4 and 5) (Table 4). The mean levels of both
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Fig. 2. The change in postdialysis weight is
shown for the dose intervention (A) and the
flux intervention (B). In each panel, the ad-
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Fig. 7. The change in upper arm circumfer-
ence is shown for the dose intervention (A)
and the flux intervention (B). In each panel,
the adjusted values for the low or standard
group are denoted (•) and the adjusted values
for the high group are denoted (◦). Diamonds
indicate unadjusted mean changes for those
patients surviving to their respective follow-
up time points in the low or standard group
() and high group (
).
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Table 4. Effect of dose and flux interventions using the informative censoring model (model 1) and 3 years of follow-up
Average treatment effects over the first 3 years of follow-up
Dose effect Flux effect
Factor Effect ± SE P value Effect ± SE P value
Nephelometry albumin g/dL −0.018 ± 0.014 0.19 −0.003 ± 0.014 0.84
Postdialysis weight kg −0.22 ± 0.26 0.41 0.05 ± 0.26 0.85
Equilibrated protein catabolic rate g/kg/day 0.019 ± 0.007 0.007 −0.001 ± 0.007 0.84
Adjusted energy intake kcal/kg/day −0.49 ± 0.37 0.19 0.33 ± 0.37 0.38
Adjusted protein intake g/kg/day −0.017 ± 0.017 0.32 0.029 ± 0.017 0.085
Calf circumference cm 0.02 ± 0.13 0.85 0.31 ± 0.13 0.015
Upper arm circumference cm 0.19 ± 0.16 0.24 0.35 ± 0.16 0.031
Appetite assessment (5-point Likert scale) 0.0003 ± 0.042 0.99 −0.058 ± 0.042 0.17
P value for dose or flux effect on each nutritional factor.
upper arm and calf circumference declined throughout
3 years of follow-up in all treatment groups (Figs. 6 and
7). For years 1, 2, and 3, however, the mean ± SE declines
in upper arm and calf circumferences averaged 0.35 ±
0.16 cm (P = 0.031) and 0.31 ± 0.13 (P = 0.015) cm less,
respectively, in the high flux compared to the low flux
group. These differences represent 1.2% and 0.9%, re-
spectively of the mean baseline values for these factors.
Finally, the appetite assessment score indicated an overall
decline in appetite over the follow-up period of the study,
but did not differ significantly between the dose and flux
groups (Table 4).
Time-to-event model, including death (method 2) and
time-to-event model, censoring death (method 3). Table 1
summarizes time-to-event analyses of the effects of the
dose intervention on the designated declines in the nu-
tritional indices or death (method 2) and the occurrence
of the same designated declines in the nutritional indices
while censoring death (method 3). For example, in the
analysis of the composite albumin event outcome us-
ing method 2, 54.8% of patients were counted as having
events, including 26.8% of patients who had a decline in
serum albumin levels by the 15% threshold and an addi-
tional 28.0% of patients who died. In comparison, in the
analysis censoring death (method 3), only the 26.8% of
patients with the 15% albumin decline were counted as
having events. The high dose arm was associated with a
statistically significant reduction in the risk of the com-
posite outcome of either a 15% decline in equilibrated
protein catabolic rate from baseline or death (RR = 0.86,
95% CI 0.78–0.95, P = 0.002) as well as a statistically sig-
nificant reduction in the risk of a 15% or greater decline in
equilibrated protein catabolic rate alone while censoring
death (RR = 0.89, 95% CI 0.80–0.98, P = 0.021). With the
exception of a borderline significant effect of dose on the
composite outcome of a decline in calf circumference or
death (which was not replicated by the analysis of mean
change in calf circumference), there were no significant
effects of the dose intervention on any of the other nu-
tritional parameters, regardless of whether deaths were
censored or included as part of a composite outcome.
Table 2 provides results for the parallel analyses exam-
ining the flux intervention. The high flux intervention was
associated with a statistically significant reduction in the
risk of the composite outcome of either a ≥4% decline
in calf circumference or death (RR = 0.81, 95% CI 0.69–
0.93, P =0.0016) with a weaker trend observed for the risk
of the ≥4% decline in calf circumference while censoring
death (RR = 0.85, 95% CI 0.68–1.02, P = 0.087). The
high flux intervention was also associated with significant
reductions in the risk of the composite event of either a
≥5% decline in upper arm circumference or death (RR =
0.80, 95% CI 0.68–0.92, P = 0.0008) and in the risk of a
≥5% decline in upper arm circumference while censoring
death (RR = 0.79, 95% CI 0.63–0.95, P = 0.009).
DISCUSSION
The HEMO Study is the largest published longitudi-
nal study of nutritional parameters in chronic hemodial-
ysis patients. The strengths of this study include the large
number of patients followed, the randomized nature of
the dose and flux intervention and the collection of data
in a standardized manner, including annual retraining
of all staff. More than 1800 patients were followed for
an average of 2.8 years with monthly measurements of
serum albumin, equilibrated protein catabolic rate and
body weight and yearly measurements of anthropomet-
ric, dietary intake, and self-reported appetite data. Di-
etitians were trained at baseline and recertified annually
for the collection of nonlaboratory nutritional measures.
Our study is unique among nutritional studies in mainte-
nance hemodialysis patients, as the analysis of nutritional
outcomes was conducted by several different methods in
order to account for the high rate of patient attrition.
Nutritional parameters that are affected similarly by the
dose and flux interventions in several statistical models
may suggest that the findings are robust. It is important to
note that the HEMO Study was not a dietary nutritional
intervention study. The goal of the HEMO Study dieti-
tians was to monitor nutritional status and only intervene
if a nutritional action item were reached.
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There is considerable ambiguity in the evaluation of the
average change in the nutritional parameters over time
due to the high rate of attrition experienced by the dial-
ysis patients in this study. However, with the exception
of adjusted protein and energy intake, there was a slow,
steady, but modest decline in the mean values of all nutri-
tional parameters during follow-up that was consistently
seen under a wide range of alternative models for dealing
with dropout, although the magnitude of the estimated
decline differs substantially depending on what assump-
tions are made. Using our basic informative censoring
model, serum albumin levels declined by approximately
0.21 g/dL over a follow-up period of 3 years. Data from
epidemiologic studies suggest that the risk of death in-
creases by approximately 10% to 15% even for this small
mean decline in serum albumin levels; therefore, this de-
cline may be clinically important [47, 48]. Most inves-
tigators have shown that serum albumin levels increase
during the first six months of dialysis [49–51] followed
by a decline in values during the second year of main-
tenance hemodialysis therapy [52]. Results from several
small studies have shown that an increase in either en-
ergy or protein intake can increase serum albumin levels
by 0.5 g/dL to 1.0 g/dL [14, 15]. Other interventions in
which protein or energy intake were increased did not
result in a statistically significant increase in serum albu-
min levels; perhaps because they involved small numbers
of patients and/or they were not randomized trials [2, 16–
19]. In addition, there does not appear to be any reported
benefit of high flux membranes on serum albumin levels
[24]; however, data on this intervention is quite limited.
It is therefore not surprising that the mean serum albu-
min levels in a random sample of chronic hemodialysis
patients in usual clinical practice has not changed appre-
ciably in the nine years since the Centers for Medicare
and Medicaid have conducted the Clinical Performance
Measures Project [53].
There were no significant changes in protein or energy
intake during follow-up in the patient cohort. Although
this observation may appear to be encouraging, it is im-
portant to note that 94% of patients did not meet the
Kidney/Disease Outcome Quality Initiative (K/DOQI)
guidelines for energy intake [54] at some point in the
study and 62% of patients never did. Similarly, 97%
of patients did not meet the K/DOQI protein intake
guidelines [55] at least once during the study period and
83% of them failed to do so at all. There are few stud-
ies that have reported on longitudinal changes in pro-
tein intake in chronic dialysis patients. In a group of 26
hemodialysis patients, mean protein intake was 0.79 ±
0.04 g/kg/day at initiation of dialysis, 0.79 ± 0.03 g/kg at 3
months after starting dialysis (P = 0.64 versus initiation),
and 1.19 ± 0.04 g/kg/day at 6 to 9 months after start-
ing dialysis (P < 0.005 versus 0 months and 3 months)
[56].
There was a small decline in the anthropometric mea-
sures observed in the HEMO Study. The small 2.7 kg
mean decline in weight over 3 years may reflect, in part,
the frequent monitoring of weight change in the HEMO
Study, with dietitian intervention for a change in weight
of greater than 10% from baseline. There did not ap-
pear to be any beneficial effect of either the dose or flux
interventions on the prevention of weight loss. Variable
findings have been reported in other small longitudinal
studies, including a decrease over time [5, 49], an initial
increase followed by a decrease [57] and no change [52].
The effect of dialysis membranes on changes in weight
has also been contradictory [24, 25].
In contrast to the absence of demonstrable effects on
serum albumin and weight, however, high flux appeared
to slow the decline in upper arm circumference and calf
circumference. The P values for the effect of the flux in-
tervention on arm circumference for the three analysis
methods ranged from <0.001 to 0.031, while the P val-
ues for the effect of flux on calf circumference ranged
from 0.002 to 0.087. The magnitudes of the effects on the
mean changes over time were small, however, represent-
ing 1.2% and 0.9% of the mean baseline values for arm
and calf circumferences, respectively. There was no clear
evidence that the dose intervention altered the decline in
either arm or calf circumference. These results are consis-
tent with the finding that there was no significant change
in body weight seen with either the dose or flux interven-
tions. Little data are available from other clinical trials
regarding the change in anthropometric values over time
and further research is needed to determine the mecha-
nisms that may explain this observation.
The high dose intervention did appear to result in
slightly higher values of equilibrated protein catabolic
rate compared to the standard dose under both time-
to-event models and the informative censoring model.
An initial difference in equilibrated protein catabolic rate
values occurred at the first follow-up in the first 3 months
after randomization, and this difference between the high
and standard dose generally persisted throughout the re-
mainder of the study. This initial change in the protein
catabolic rate with a change in the dose of dialysis has
been reported elsewhere [25, 26]. Although the random-
ized design of the HEMO Study should have prevented
the form of mathematical coupling between measure-
ment errors in equilibrated protein catabolic rate and
Kt/V that has been reported elsewhere [58], it is possible
that the apparent small effect of the dose intervention
on equilibrated protein catabolic rate could be an arti-
fact related to as yet unidentified discrepancies between
the idealized kinetic models used in the study and the ac-
tual biology associated with urea disequilibrium during
dialysis. The appearance of a greater overall decline in
equilibrated protein catabolic rate over time compared
to dietary protein intake (see Figs. 3 and 4) may reflect
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effects of anabolism or catabolism on equilibrated pro-
tein catabolic rate or possible biases in dietary report-
ing. It is more likely, however, to be explained in part by
the standardization of equilibrated protein catabolic rate
by the kinetically modeled volume of urea distribution,
which did not decline over time (data not shown) as did
the postdialysis weight that was used for standardization
of dietary protein intake.
Prior studies using the ADAT have demonstrated
an association between increasing appetite assessment
scores and increasing protein and energy intake [59]. In
the HEMO Study longitudinal analysis, there was no sig-
nificant change in dietary energy or protein intake over
time or by the dose or flux intervention. Thus, it is not
surprising that neither the dose or flux intervention had
any statistically significant effect on the ADAT.
There are several limitations to this study. Neither di-
etary protein nor energy intake was affected by the dose
or flux interventions; however, the lack of sensitivity of
this measurement may account for the lack of effects ob-
served. The food record data was obtained infrequently,
for a 2-day period on a yearly basis. These infrequent as-
sessments of protein and energy intake may have masked
subtle changes in these intakes over time [60]. It should
also be noted that the changes in nutritional status re-
ported for HEMO Study patients all occurred in the
setting of adequate dialysis as defined by the K/DOQI
guidelines [61] and without the use of cuprophane mem-
branes. Thus, these findings cannot be generalized to pa-
tients who do not meet K/DOQI guidelines for dialysis
dose or use cuprophane membranes [62, 63]. In addition,
patients who could not achieve the high dose adequacy
goal were also excluded from the study; in the randomized
cohort, only 3% of patients weighed more than 100 kg.
Thus, these findings cannot be generalized to morbidly
obese patients. It is also important to note that the pa-
tients in the HEMO Study were followed by dietitians
in a closely monitored environment that may not be rep-
resentative of the intensity of monitoring that occurs in
clinical practice due to staffing and other considerations
[64]. This environment included the provision of oral nu-
tritional supplements without charge if the study dietitian
determined that they were indicated. Lack of financial
resources may prevent some hemodialysis patients from
purchasing oral nutritional supplements. Finally, the in-
terpretation of the results of this paper must also consider
the issue of multiple comparisons [65] since the effects of
two different interventions on seven different outcomes
were considered. Formal adjustment for multiple com-
parisons was not performed due to ambiguities in defin-
ing the appropriate adjustment when multiple analysis
methods are used, as is the case here. Thus, even with
critical value of 0.01, the possibility of a spurious positive
finding due to evaluation of multiple outcomes cannot be
ruled out.
Thus, all the nutritional parameters, except for dietary
protein and energy intake, exhibited a small but statisti-
cally significant decline over an average follow-up period
of 3 years. Neither the dose nor the flux interventions
influenced the primary nutritional outcome of serum al-
bumin level or the nutritional action item of postdialy-
sis weight. The high flux intervention of the study was
associated with a slower decline in upper arm and mid-
arm circumference over time and a smaller initial decline
in equilibrated protein catabolic rate values. These ef-
fects were clinically subtle, however. Thus, it is unlikely
that using current technology there will be a significant
impact of dialysis dose or dialysis flux on nutritional out-
comes when dialysis is provided three times per week, de-
spite patients receiving frequent nutritional anticipatory
guidance.
APPENDIX
A mixture informative censoring [38–40] was used to estimate the
mean changes in a nutritional status index within each treatment group,
using three censoring variables: (1) the duration of follow-up, (2) a bi-
nary variable specifying whether follow-up was terminated early due
to death, and (3) the interaction term between these two factors. The
model also allowed for an accelerated decline in the 6 months prior to
death, which was observed for most of the nutritional parameters. The
conditional mean changes were estimated while controlling for seven
prespecified baseline factors (age, gender, race, diabetic status, years
of prior dialysis, baseline albumin, and baseline ICED score) and the
baseline level of the nutritional status index as covariates. The model
allowed unstructured covariances for the changes in the nutritional pa-
rameters to the respective follow-up assessments, thus allowing for any
pattern of correlations in the changes over time. In the second step of
the analysis, the results obtained conditionally on the values of the cen-
soring variables in the first step are averaged over the distributions of
the censoring variables within each of the treatment groups.
Sensitivity analyses for method 1. Informative censoring models re-
quire untestable assumptions regarding the changes in the outcome
variables that would have been observed had the patient not been lost
due to attrition [40–42]. To address this issue, the mean changes in the
nutritional variables were evaluated under three different models which
differ in the way they extrapolate the values observed in the final year
prior to death to time points after death. The first model incorporates
the accelerated decline in the final 6 months prior to death, but then as-
sumes that the rate of mean change after death reverts to the mean rate
of change for patients who did not die until at least 6 months after the
current time point. This is the model used for the “main analysis” pre-
sented in Figures 1 to 7 and Table 4. The second model assumes that the
accelerated decline observed in the 6 months prior to death persists
throughout the remainder of follow-up. The third model excludes the
accelerated decline both during the final year prior to death and sub-
sequently in the remainder of follow-up. Figure 8 illustrates the results
for the three models for serum albumin. These three informative cen-
soring models, as well as the analysis of mean changes to each follow-up
year without adjustment for censoring, all yielded similar results with
respect to the comparisons of the dose and flux groups. The similarity of
results suggests that the main findings (from model 1) are not artifacts
of a particular method of accounting for dropout. On the other hand,
for several nutritional indices, the overall estimate of the rate of mean
decline over time did differ substantially among the different models.
Thus, while the differences between the treatment groups are similar
for each model, Figure 8 shows uncertainty in the assessment of the
overall mean rate of decline within the treatment groups. This uncer-
tainty reflects an inherent indeterminacy in the description of change
in a cohort with a high rate of attrition.
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Fig. 8. The estimated mean change in serum albumin levels using raw
mean data and using three different informative censoring models. Data
areshown for the standard dose group. An explanation of the three
different models is provided in the Appendix.
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